See more : Imugene Limited (IMU.AX) Income Statement Analysis – Financial Results
Complete financial analysis of Lobe Sciences Ltd. (LOBE.CN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Lobe Sciences Ltd., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Saptarishi Agro Industries Ltd (SPTRSHI.BO) Income Statement Analysis – Financial Results
- Manitou BF SA (MTU.PA) Income Statement Analysis – Financial Results
- Xiwang Special Steel Company Limited (1266.HK) Income Statement Analysis – Financial Results
- Keiyo Gas Co., Ltd. (9539.T) Income Statement Analysis – Financial Results
- Time Out Group plc (TMO.L) Income Statement Analysis – Financial Results
Lobe Sciences Ltd. (LOBE.CN)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.lobesciences.com
About Lobe Sciences Ltd.
Lobe Sciences Ltd., a life sciences company, focuses on the research and development of psychedelic medicines. It develops psilocybin-based therapeutics in combination with N-acetylcysteine for the treatment of mild traumatic brain injuries and post-traumatic stress disorder, as well as devices for the efficient application of medications. The company was formerly known as Greenstar Biosciences Corp. and changed its name to Lobe Sciences Ltd. in November 2020. Lobe Sciences Ltd. is headquartered in Vancouver, Canada.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 840.53K | 0.00 | 0.00 | 884.84K | 773.79K | 567.43K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 67.71K | 10.22K | 0.00 | 0.00 | 2.21M | 151.17K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 772.83K | -10.22K | 0.00 | 884.84K | -1.44M | 416.26K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 91.94% | 0.00% | 0.00% | 100.00% | -186.19% | 73.36% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 1.25M | 418.34K | 1.37M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 2.60M | 3.45M | 3.24M | 1.80M | 2.80M | 2.10M | 51.94K | 45.78K | 62.04K | 108.49K | 137.11K | 94.48K | 91.00K |
| Selling & Marketing | 289.03K | 248.13K | 1.70M | 936.70K | 472.73K | 52.76K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 2.88M | 3.69M | 4.94M | 2.73M | 3.27M | 148.40K | 51.94K | 45.78K | 62.04K | 108.49K | 137.11K | 94.48K | 91.00K |
| Other Expenses | 0.00 | 10.22K | 2.29K | 561.48K | 371.04K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 4.13M | 4.12M | 6.32M | 3.29M | 3.64M | 148.40K | 51.94K | 45.78K | 62.04K | 108.49K | 137.11K | 94.48K | 91.00K |
| Cost & Expenses | 4.20M | 4.12M | 6.32M | 3.29M | 3.64M | 148.40K | 51.94K | 45.78K | 62.04K | 108.49K | 137.11K | 94.48K | 91.00K |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 68.52K | 0.00 | 308.00 | 886.00 | 2.07K | 3.16K | 1.38K | 0.00 |
| Interest Expense | 38.64K | 13.62M | 0.00 | 43.05K | 0.00 | 0.00 | 144.00 | 308.00 | 886.00 | 2.07K | 3.16K | 1.38K | 0.00 |
| Depreciation & Amortization | 43.70K | 10.22K | 215.90K | 561.48K | 371.04K | 246.20K | 288.00 | 10.50K | 109.69K | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -4.40M | -11.96M | -6.16M | -2.71M | -383.40K | -148.40K | -51.94K | -35.28K | 47.66K | -108.49K | -137.11K | -94.48K | -91.00K |
| EBITDA Ratio | -523.75% | 0.00% | 0.00% | -213.67% | -542.27% | -26.15% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -3.36M | 1.37M | 6.85M | -2.45M | -4.41M | -148.40K | -51.94K | -45.78K | -62.04K | -108.49K | -137.11K | -94.48K | -91.00K |
| Operating Income Ratio | -399.67% | 0.00% | 0.00% | -277.12% | -569.46% | -26.15% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -1.14M | -8.14M | -17.47M | -974.19K | 2.11M | 107.00 | 144.00 | -10.19K | -108.80K | 2.07K | 3.16K | 1.38K | 0.00 |
| Income Before Tax | -4.50M | -12.25M | -23.84M | -3.44M | -754.43K | -148.29K | -51.80K | -55.97K | -170.84K | -106.42K | -133.96K | -93.10K | -91.00K |
| Income Before Tax Ratio | -535.65% | 0.00% | 0.00% | -388.33% | -97.50% | -26.13% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 205.00K | 13.62M | -1.02M | 1.03K | -1.54M | -246.20K | -288.00 | -308.00 | -886.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income | -4.71M | -25.87M | -22.82M | -3.44M | 785.98K | -148.29K | -51.80K | -55.97K | -170.84K | -106.42K | -133.96K | -93.10K | -91.00K |
| Net Income Ratio | -560.04% | 0.00% | 0.00% | -388.45% | 101.58% | -26.13% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.05 | -0.68 | -0.70 | -0.27 | 0.10 | -0.20 | -0.07 | -0.08 | -0.24 | -0.15 | -0.19 | -0.16 | -1.18 |
| EPS Diluted | -0.05 | -0.68 | -0.70 | -0.27 | 0.10 | -0.20 | -0.07 | -0.08 | -0.24 | -0.15 | -0.19 | -0.16 | -1.18 |
| Weighted Avg Shares Out | 104.35M | 37.86M | 32.49M | 12.55M | 7.97M | 741.67K | 733.90K | 700.00K | 699.89K | 691.67K | 691.67K | 567.19K | 76.81K |
| Weighted Avg Shares Out (Dil) | 104.35M | 37.86M | 32.49M | 12.55M | 7.97M | 741.67K | 733.90K | 700.00K | 699.89K | 691.67K | 691.67K | 567.19K | 76.81K |
Source: https://incomestatements.info
Category: Stock Reports